Protect yourself, protect your loved ones and protect others.
COVID-19 infections are accelerating at an alarming pace. The virus has already infected more than 60 million people and more than 1.5 million have lost their lives, globally. Successful vaccines will reduce the risk of infection. However, global availability and effectiveness during dosage intervals remains a challenge. Moreover, based on the past experience with other viral respiratory infections and virus strain mutation capabilities, there is little reason to believe that COVID-19 will go away any time soon. As such, wearing a mask will be the new 'normal' lifestyle. Along with other WHO guidelines for maintaining six feet of social distance, washing hands regularly and hygienic lifestyle, wearing a good quality mask is a must, as COVID-19 infected victims may be asymptomatic or pre-symptomatic.
Through robust technological innovation, Malaysian international sportswear manufacturer Prolexus Berhad (Prolexus) has expanded its product categories into personal protective equipment (PPE) through the development of ProXmask™ functional protective mask series.
Prolexus aspires to deliver the best protective functional and reusable facemask to ensure effective protection for everyone against the virus. ProXmask™ is a revolutionary protection mask with water repellency and enhanced microfiltration technology. Its water repellency feature enables effective shielding from water droplets containing virus and bacteria, while an innovative self-developed, dense network of microfibre structure captures viruses and bacteria down to a microscopic scale, 1,000 times smaller than a millimetre.
Prolexus has also unveiled its ProX anti-virus technology which inactivates bacteria and viruses, including >99% SARS-CoV-2, the virus responsible for COVID-19. The molecular mechanism involves neutralisation of the negatively charged virus cell upon contact with ProX anti-virus fabric, which subsequently leads to rapid destruction of the glycoprotein layers and release of non-infectious ribonucleic acid (RNA).
Additionally, ProX microfiltration technology also enables 95 per cent bacterial and particle filtration efficiencies for up to 60 washes. The microfiltration technology was developed based on filtration performance of 0.1-micron sized particles, as coronaviruses generally have average diameters of 0.12 micron.
ProXmask comes in three versions: ProXmask 90, ProXmask 90V and ProXmask 95V, varied through its unique protective features.
ProXmask is registered with the US Food and Drug Administration (FDA) for face mask for general public/healthcare personnel per Immediately in Effect Guidance (IIE Guidance). It also complies with European Union (EU) standards and regulations and in the progress of CE registration as a reusable mask intended for general public use. These registrations are expected to expand ProXmask export market horizon to the US and EU.
Prolexus is confident that the utilisation of technology through ProXmask will reduce public risk of infection and help the world to fight the COVID-19 spread. The reusability of the mask makes it an eco-friendly, cost effective and a sustainable solution compared to the use of disposal masks. With its anti-virus and microfiltration technology staying effective up to 60 wash cycles, the usage lifespan of one ProXmask will be equivalent to at least 120 disposal masks, bringing down the cost per usage.
Backed by its advanced ProX anti-virus technology, Prolexus is set to explore innovative market segments such as personal protective apparel, a new emerging sportswear category. Prolexus marketing is actively working towards serving prospective clients with interest in protective and functional activewears.
For enquiries/partnership, please call 1700-81-8398, email firstname.lastname@example.org or visit www.prolexus.com.my/proxmask